ArticleInvestigational new drugs2022

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.

Joleen M Hubbard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.